Anaplastic large cell lymphoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Brentuximab vedotin monotherapy Variant #01 | — | R 85 244 | 21d | ~16.7 mo | — | ~25 | ~R 2 131 097 PFS proxy · indirect | 1 |
DHAP Variant #01 | — | R 3 777 | 28d | — | — | — | — | — |
GDP Variant #01 | — | R 3 565 | 21d | — | — | — | — | — |
3 of 3 regimens shown